TiumBio티움바이오
321550 · KOSDAQ · ₩321550 · 티움바이오
₩3,905▼ ₩140 (3.46%)End-of-day · Oct 27, 2026 · End-of-day prices.
Margins
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Gross margin | 39.5% | 41.0% | — | — | — | — |
| Operating margin | −107.3% | −131.4% | −275.3% | −568.1% | −281.2% | −57,566.2% |
| Net margin | −122.7% | −152.9% | −346.7% | −388.6% | −344.4% | −56,785.6% |
Growth (year on year)
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Revenue growth | +22.0% | +80.9% | +38.7% | −46.3% | +15,952.8% | — |
| Operating income growth | +0.4% | +13.7% | +32.8% | −8.5% | +21.6% | — |
| Net income growth | +2.0% | +20.2% | −23.7% | +39.4% | +2.6% | — |
Returns
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Return on equity | −47.9% | −40.3% | −38.4% | −29.0% | −42.3% | −36.8% |
| Return on assets | −19.4% | −18.3% | −20.8% | −17.6% | −29.9% | −28.4% |
Leverage and liquidity
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Liabilities to equity | 179.9% | 161.1% | 111.4% | 69.9% | 54.5% | 25.9% |
| Net debt to equity | −55.0% | −39.7% | −41.9% | −18.4% | −21.3% | 12.1% |
| Current ratio | 93.2% | 110.8% | 149.8% | 388.4% | 133.8% | 938.0% |
Calculated from filed financial statements. TTM = trailing 12 months.
Also known as: TiumBio / 티움바이오 / 321550 / KRX:321550
Source: KRX statistical information